

**HPTN 069 - Maraviroc Phase II PrEP
Data as of 31 January 2016**

**Accrual Summary by Site
MALE**

Site	DAIDS Site ID	Activation Date	First Enrollment Date	Last Enrollment Date ¹	Duration of Accrual ² (weeks)	Enrollment Target ³	Total Enrolled	Average Enrolled per Week	Percent Enrolled
Baltimore, MD	201	11SEP2012	08NOV2012	24APR2014	168.6	25	23	0.1	92.0%
Boston, MA	31785	15AUG2012	05SEP2012	27SEP2013	177.7	50	50	0.3	100.0%
Chapel Hill/Raleigh, NC	3201	28JUN2012	25JUL2012	29OCT2013	183.7	35	35	0.2	100.0%
Cleveland, OH	2501	11SEP2012	28SEP2012	01OCT2013	174.4	30	33	0.2	110.0%
Los Angeles, CA	601	13JUL2012	06AUG2012	01APR2014	182.0	25	30	0.2	120.0%
New York, NY	7804	15AUG2012	12SEP2012	23AUG2013	176.7	25	29	0.2	116.0%
Philadelphia, PA	6201	15AUG2012	18SEP2012	22AUG2013	175.9	30	32	0.2	106.7%
Pittsburgh, PA	1001	27SEP2012	04DEC2012	19FEB2014	164.9	25	25	0.2	100.0%
San Francisco, CA	30305	03AUG2012	03OCT2012	04OCT2013	173.7	50	50	0.3	100.0%
San Juan, PR	5401	19OCT2012	17DEC2012	25SEP2013	163.0	25	22	0.1	88.0%
Seattle, WA	1401	28AUG2012	19OCT2012	11SEP2013	171.4	30	27	0.2	90.0%
Washington DC	31608	28AUG2012	09NOV2012	19AUG2013	168.4	50	50	0.3	100.0%
Total	missing	28JUN2012	25JUL2012	24APR2014	183.7	400	406	2.2	101.5%

¹Date of most recent enrollment as of 31 January 2016.

²Duration of accrual based on first enrollment date.

³Number of unassigned enrollment slots = 0.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of 31 January 2016**

**Accrual Summary by Site
FEMALE**

Site	DAIDS Site ID	Activation Date	First Enrollment Date	Last Enrollment Date ¹	Duration of Accrual ² (weeks)	Enrollment Target ³	Total Enrolled	Average Enrolled per Week	Percent Enrolled
Baltimore, MD	201	11SEP2012	18AUG2014	25NOV2014	76.0	20	8	0.1	40.0%
Boston, MA	31785	15AUG2012	29MAY2013	21JUL2014	139.7	20	15	0.1	75.0%
Chapel Hill/Raleigh, NC	3201	28JUN2012	15MAR2013	07NOV2014	150.4	20	21	0.1	105.0%
Cleveland, OH	2501	11SEP2012	17APR2013	26NOV2014	145.7	12	18	0.1	150.0%
Los Angeles, CA	601	13JUL2012	10DEC2013	25NOV2014	111.9	20	5	0.0	25.0%
New York, NY	7804	15AUG2012	25JUN2013	25NOV2014	135.9	12	16	0.1	133.3%
Newark, NJ	31786	20MAR2013	18APR2013	07OCT2014	145.6	20	32	0.2	160.0%
Philadelphia, PA	6201	15AUG2012	09MAY2013	19NOV2014	142.6	12	15	0.1	125.0%
Pittsburgh, PA	1001	27SEP2012	14APR2014	01DEC2014	94.0	20	15	0.2	75.0%
San Juan, PR	5401	19OCT2012	03JUN2013	22SEP2014	139.0	12	15	0.1	125.0%
Seattle, WA	1401	28AUG2012	13JUN2013	15OCT2014	137.6	12	8	0.1	66.7%
Washington DC	31608	28AUG2012	26JUN2013	18APR2014	135.7	20	20	0.1	100.0%
Total	missing	28JUN2012	15MAR2013	01DEC2014	150.4	200	188	1.3	94.0%

¹Date of most recent enrollment as of 31 January 2016.

²Duration of accrual based on first enrollment date.

³Number of unassigned enrollment slots = 0.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Accrual Summary and Accrual by Calendar Month and Site
MALE**

	Total	Baltimore, MD	Boston, MA	Chapel Hill/ Raleigh, NC	Cleveland, OH					
Activation Date	28JUN2012	11SEP2012	15AUG2012	28JUN2012	11SEP2012					
First Enrollment Date	25JUL2012	08NOV2012	05SEP2012	25JUL2012	28SEP2012					
Summary										
Total Enrolled	406	23	50	35	33					
Enrollment Target ¹	400	25	50	35	30					
Percent Enrolled	101.5%	92.0%	100.0%	100.0%	110.0%					
Accrual										
Calendar Month of Accrual	Month ²	Cumulative ³	Month	Cumulative	Month	Cumulative	Month	Cumulative	Month	Cumulative
JUL2012	1/1(100.0%)	1/1(100.0%)					1/1(100.0%)	1/1(100.0%)		
AUG2012	4/5(80.0%)	5/6(83.3%)					3/2(150.0%)	4/3(133.3%)		
SEP2012	15/15(100.0%)	20/21(95.2%)			5/5(100.0%)	5/5(100.0%)	4/2(200.0%)	8/5(160.0%)	1/1(100.0%)	1/1(100.0%)
OCT2012	28/28(100.0%)	48/49(98.0%)			3/6(50.0%)	8/11(72.7%)	2/2(100.0%)	10/7(142.9%)	6/3(200.0%)	7/4(175.0%)
NOV2012	20/36(55.6%)	68/85(80.0%)	1/3(33.3%)	1/3(33.3%)	2/6(33.3%)	10/17(58.8%)	0/2(0.0%)	10/9(111.1%)	1/3(33.3%)	8/7(114.3%)
DEC2012	20/42(47.6%)	88/127(69.3%)	1/3(33.3%)	2/6(33.3%)	0/6(0.0%)	10/23(43.5%)	4/2(200.0%)	14/11(127.3%)	1/3(33.3%)	9/10(90.0%)
JAN2013	38/43(88.4%)	126/170(74.1%)	0/3(0.0%)	2/9(22.2%)	8/6(133.3%)	18/29(62.1%)	4/2(200.0%)	18/13(138.5%)	3/3(100.0%)	12/13(92.3%)
FEB2013	32/43(74.4%)	158/213(74.2%)	0/3(0.0%)	2/12(16.7%)	8/6(133.3%)	26/35(74.3%)	3/2(150.0%)	21/15(140.0%)	0/3(0.0%)	12/16(75.0%)
MAR2013	25/44(56.8%)	183/257(71.2%)	0/3(0.0%)	2/15(13.3%)	1/6(16.7%)	27/41(65.9%)	2/3(66.7%)	23/18(127.8%)	5/3(166.7%)	17/19(89.5%)
APR2013	36/44(81.8%)	219/301(72.8%)	1/3(33.3%)	3/18(16.7%)	5/6(83.3%)	32/47(68.1%)	3/3(100.0%)	26/21(123.8%)	2/3(66.7%)	19/22(86.4%)
MAY2013	41/38(107.9%)	260/339(76.7%)	4/2(200.0%)	7/20(35.0%)	7/3(233.3%)	39/50(78.0%)	2/3(66.7%)	28/24(116.7%)	5/3(166.7%)	24/25(96.0%)
JUN2013	24/25(96.0%)	284/364(78.0%)	2/1(200.0%)	9/21(42.9%)	1/ ()	40/50(80.0%)	0/3(0.0%)	28/27(103.7%)	3/2(150.0%)	27/27(100.0%)
JUL2013	29/20(145.0%)	313/384(81.5%)	3/1(300.0%)	12/22(54.5%)	2/ ()	42/50(84.0%)	3/3(100.0%)	31/30(103.3%)	1/2(50.0%)	28/29(96.6%)
AUG2013	41/11(372.7%)	354/395(89.6%)	4/1(400.0%)	16/23(69.6%)	5/ ()	47/50(94.0%)	0/3(0.0%)	31/33(93.9%)	2/1(200.0%)	30/30(100.0%)
SEP2013	20/3(666.7%)	374/398(94.0%)	1/1(100.0%)	17/24(70.8%)	3/ ()	50/50(100.0%)	0/1(0.0%)	31/34(91.2%)	1/ ()	31/30(103.3%)
OCT2013	11/2(550.0%)	385/400(96.3%)	2/1(200.0%)	19/25(76.0%)	0/ ()	50/50(100.0%)	0/1(0.0%)	31/35(88.6%)	2/ ()	33/30(110.0%)
NOV2013	2/ ()	387/400(96.8%)	0/ ()	19/25(76.0%)	0/ ()	50/50(100.0%)	0/ ()	31/35(88.6%)	0/ ()	33/30(110.0%)
DEC2013	2/ ()	389/400(97.3%)	0/ ()	19/25(76.0%)	0/ ()	50/50(100.0%)	0/ ()	31/35(88.6%)	0/ ()	33/30(110.0%)
JAN2014	3/ ()	392/400(98.0%)	0/ ()	19/25(76.0%)	0/ ()	50/50(100.0%)	0/ ()	31/35(88.6%)	0/ ()	33/30(110.0%)

¹Number of unassigned enrollment slots = 0.

²Number of participants actually enrolled (as numerator) and number of participants targeted to enroll (as denominator) in a given calendar month. Percentages of actual vs. target enrollment are given in parentheses.

³Number of participants actually enrolled and number of participants targeted to enroll up to a given calendar month.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Accrual Summary and Accrual by Calendar Month and Site
MALE**

	Total	Baltimore, MD	Boston, MA	Chapel Hill/ Raleigh, NC	Cleveland, OH
FEB2014	6/ () 398/400(99.5%)	1/ () 20/25(80.0%)	0/ () 50/50(100.0%)	0/ () 31/35(88.6%)	0/ () 33/30(110.0%)
MAR2014	5/ () 403/400(100.8%)	1/ () 21/25(84.0%)	0/ () 50/50(100.0%)	0/ () 31/35(88.6%)	0/ () 33/30(110.0%)
APR2014	3/ () 406/400(101.5%)	2/ () 23/25(92.0%)	0/ () 50/50(100.0%)	0/ () 31/35(88.6%)	0/ () 33/30(110.0%)
Average Enrolled per Month	18.4	1.2	2.5	1.4	1.6

¹Number of unassigned enrollment slots = 0.

²Number of participants actually enrolled (as numerator) and number of participants targeted to enroll (as denominator) in a given calendar month. Percentages of actual vs. target enrollment are given in parentheses.

³Number of participants actually enrolled and number of participants targeted to enroll up to a given calendar month.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Accrual Summary and Accrual by Calendar Month and Site
MALE**

	Total	Los Angeles, CA	New York, NY	Philadelphia, PA	Pittsburgh, PA					
Activation Date	28JUN2012	13JUL2012	15AUG2012	15AUG2012	27SEP2012					
First Enrollment Date	25JUL2012	06AUG2012	12SEP2012	18SEP2012	04DEC2012					
Summary										
Total Enrolled	406	30	29	32	25					
Enrollment Target ¹	400	25	25	30	25					
Percent Enrolled	101.5%	120.0%	116.0%	106.7%	100.0%					
Accrual										
Calendar Month of Accrual	Month ²	Cumulative ³	Month	Cumulative	Month	Cumulative	Month	Cumulative	Month	Cumulative
JUL2012	1/1(100.0%)	1/1(100.0%)								
AUG2012	4/5(80.0%)	5/6(83.3%)	1/3(33.3%)	1/3(33.3%)						
SEP2012	15/15(100.0%)	20/21(95.2%)	0/3(0.0%)	1/6(16.7%)	1/2(50.0%)	1/2(50.0%)	4/2(200.0%)	4/2(200.0%)		
OCT2012	28/28(100.0%)	48/49(98.0%)	3/3(100.0%)	4/9(44.4%)	3/3(100.0%)	4/5(80.0%)	5/3(166.7%)	9/5(180.0%)		
NOV2012	20/36(55.6%)	68/85(80.0%)	1/3(33.3%)	5/12(41.7%)	2/3(66.7%)	6/8(75.0%)	5/3(166.7%)	14/8(175.0%)		
DEC2012	20/42(47.6%)	88/127(69.3%)	0/2(0.0%)	5/14(35.7%)	2/3(66.7%)	8/11(72.7%)	3/3(100.0%)	17/11(154.5%)	1/3(33.3%)	1/3(33.3%)
JAN2013	38/43(88.4%)	126/170(74.1%)	1/2(50.0%)	6/16(37.5%)	4/3(133.3%)	12/14(85.7%)	2/3(66.7%)	19/14(135.7%)	3/3(100.0%)	4/6(66.7%)
FEB2013	32/43(74.4%)	158/213(74.2%)	3/2(150.0%)	9/18(50.0%)	3/3(100.0%)	15/17(88.2%)	4/3(133.3%)	23/17(135.3%)	0/3(0.0%)	4/9(44.4%)
MAR2013	25/44(56.8%)	183/257(71.2%)	1/2(50.0%)	10/20(50.0%)	2/3(66.7%)	17/20(85.0%)	0/3(0.0%)	23/20(115.0%)	1/3(33.3%)	5/12(41.7%)
APR2013	36/44(81.8%)	219/301(72.8%)	2/2(100.0%)	12/22(54.5%)	2/3(66.7%)	19/23(82.6%)	3/3(100.0%)	26/23(113.0%)	3/3(100.0%)	8/15(53.3%)
MAY2013	41/38(107.9%)	260/339(76.7%)	2/2(100.0%)	14/24(58.3%)	2/2(100.0%)	21/25(84.0%)	1/2(50.0%)	27/25(108.0%)	2/3(66.7%)	10/18(55.6%)
JUN2013	24/25(96.0%)	284/364(78.0%)	1/1(100.0%)	15/25(60.0%)	1/ ()	22/25(88.0%)	1/2(50.0%)	28/27(103.7%)	1/3(33.3%)	11/21(52.4%)
JUL2013	29/20(145.0%)	313/384(81.5%)	1/ ()	16/25(64.0%)	4/ ()	26/25(104.0%)	1/2(50.0%)	29/29(100.0%)	1/3(33.3%)	12/24(50.0%)
AUG2013	41/11(372.7%)	354/395(89.6%)	2/ ()	18/25(72.0%)	3/ ()	29/25(116.0%)	3/1(300.0%)	32/30(106.7%)	3/1(300.0%)	15/25(60.0%)
SEP2013	20/3(666.7%)	374/398(94.0%)	0/ ()	18/25(72.0%)	0/ ()	29/25(116.0%)	0/ ()	32/30(106.7%)	2/ ()	17/25(68.0%)
OCT2013	11/2(550.0%)	385/400(96.3%)	1/ ()	19/25(76.0%)	0/ ()	29/25(116.0%)	0/ ()	32/30(106.7%)	2/ ()	19/25(76.0%)
NOV2013	2/ ()	387/400(96.8%)	0/ ()	19/25(76.0%)	0/ ()	29/25(116.0%)	0/ ()	32/30(106.7%)	2/ ()	21/25(84.0%)
DEC2013	2/ ()	389/400(97.3%)	0/ ()	19/25(76.0%)	0/ ()	29/25(116.0%)	0/ ()	32/30(106.7%)	2/ ()	23/25(92.0%)
JAN2014	3/ ()	392/400(98.0%)	3/ ()	22/25(88.0%)	0/ ()	29/25(116.0%)	0/ ()	32/30(106.7%)	0/ ()	23/25(92.0%)

¹Number of unassigned enrollment slots = 0.

²Number of participants actually enrolled (as numerator) and number of participants targeted to enroll (as denominator) in a given calendar month. Percentages of actual vs. target enrollment are given in parentheses.

³Number of participants actually enrolled and number of participants targeted to enroll up to a given calendar month.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Accrual Summary and Accrual by Calendar Month and Site
MALE**

	Total	Los Angeles, CA	New York, NY	Philadelphia, PA	Pittsburgh, PA
FEB2014	6/ () 398/400(99.5%)	3/ () 25/25(100.0%)	0/ () 29/25(116.0%)	0/ () 32/30(106.7%)	2/ () 25/25(100.0%)
MAR2014	5/ () 403/400(100.8%)	4/ () 29/25(116.0%)	0/ () 29/25(116.0%)	0/ () 32/30(106.7%)	0/ () 25/25(100.0%)
APR2014	3/ () 406/400(101.5%)	1/ () 30/25(120.0%)	0/ () 29/25(116.0%)	0/ () 32/30(106.7%)	0/ () 25/25(100.0%)
Average Enrolled per Month	18.4	1.4	1.4	1.6	1.4

¹Number of unassigned enrollment slots = 0.

²Number of participants actually enrolled (as numerator) and number of participants targeted to enroll (as denominator) in a given calendar month. Percentages of actual vs. target enrollment are given in parentheses.

³Number of participants actually enrolled and number of participants targeted to enroll up to a given calendar month.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Accrual Summary and Accrual by Calendar Month and Site
MALE**

	Total	San Francisco, CA	San Juan, PR	Seattle, WA	Washington DC					
Activation Date	28JUN2012	03AUG2012	19OCT2012	28AUG2012	28AUG2012					
First Enrollment Date	25JUL2012	03OCT2012	17DEC2012	19OCT2012	09NOV2012					
Summary										
Total Enrolled	406	50	22	27	50					
Enrollment Target ¹	400	50	25	30	50					
Percent Enrolled	101.5%	100.0%	88.0%	90.0%	100.0%					
Accrual										
Calendar Month of Accrual	Month ²	Cumulative ³	Month	Cumulative	Month	Cumulative	Month	Cumulative	Month	Cumulative
JUL2012	1/1(100.0%)	1/1(100.0%)								
AUG2012	4/5(80.0%)	5/6(83.3%)								
SEP2012	15/15(100.0%)	20/21(95.2%)								
OCT2012	28/28(100.0%)	48/49(98.0%)	4/6(66.7%)	4/6(66.7%)			2/2(100.0%)	2/2(100.0%)		
NOV2012	20/36(55.6%)	68/85(80.0%)	5/6(83.3%)	9/12(75.0%)			0/3(0.0%)	2/5(40.0%)	3/4(75.0%)	3/4(75.0%)
DEC2012	20/42(47.6%)	88/127(69.3%)	3/6(50.0%)	12/18(66.7%)	1/2(50.0%)	1/2(50.0%)	3/3(100.0%)	5/8(62.5%)	1/6(16.7%)	4/10(40.0%)
JAN2013	38/43(88.4%)	126/170(74.1%)	4/6(66.7%)	16/24(66.7%)	1/3(33.3%)	2/5(40.0%)	2/3(66.7%)	7/11(63.6%)	5/6(83.3%)	9/16(56.3%)
FEB2013	32/43(74.4%)	158/213(74.2%)	2/6(33.3%)	18/30(60.0%)	2/3(66.7%)	4/8(50.0%)	1/3(33.3%)	8/14(57.1%)	5/6(83.3%)	14/22(63.6%)
MAR2013	25/44(56.8%)	183/257(71.2%)	4/6(66.7%)	22/36(61.1%)	2/3(66.7%)	6/11(54.5%)	3/3(100.0%)	11/17(64.7%)	4/6(66.7%)	18/28(64.3%)
APR2013	36/44(81.8%)	219/301(72.8%)	2/6(33.3%)	24/42(57.1%)	3/3(100.0%)	9/14(64.3%)	3/3(100.0%)	14/20(70.0%)	6/6(100.0%)	24/34(70.6%)
MAY2013	41/38(107.9%)	260/339(76.7%)	5/6(83.3%)	29/48(60.4%)	0/3(0.0%)	9/17(52.9%)	3/3(100.0%)	17/23(73.9%)	8/6(133.3%)	32/40(80.0%)
JUN2013	24/25(96.0%)	284/364(78.0%)	3/2(150.0%)	32/50(64.0%)	1/3(33.3%)	10/20(50.0%)	2/2(100.0%)	19/25(76.0%)	8/6(133.3%)	40/46(87.0%)
JUL2013	29/20(145.0%)	313/384(81.5%)	3/ ()	35/50(70.0%)	1/3(33.3%)	11/23(47.8%)	4/2(200.0%)	23/27(85.2%)	5/4(125.0%)	45/50(90.0%)
AUG2013	41/11(372.7%)	354/395(89.6%)	9/ ()	44/50(88.0%)	2/2(100.0%)	13/25(52.0%)	3/2(150.0%)	26/29(89.7%)	5/ ()	50/50(100.0%)
SEP2013	20/3(666.7%)	374/398(94.0%)	3/ ()	47/50(94.0%)	9/ ()	22/25(88.0%)	1/1(100.0%)	27/30(90.0%)	0/ ()	50/50(100.0%)
OCT2013	11/2(550.0%)	385/400(96.3%)	3/ ()	50/50(100.0%)	0/ ()	22/25(88.0%)	0/ ()	27/30(90.0%)	0/ ()	50/50(100.0%)
NOV2013	2/ ()	387/400(96.8%)	0/ ()	50/50(100.0%)	0/ ()	22/25(88.0%)	0/ ()	27/30(90.0%)	0/ ()	50/50(100.0%)
DEC2013	2/ ()	389/400(97.3%)	0/ ()	50/50(100.0%)	0/ ()	22/25(88.0%)	0/ ()	27/30(90.0%)	0/ ()	50/50(100.0%)
JAN2014	3/ ()	392/400(98.0%)	0/ ()	50/50(100.0%)	0/ ()	22/25(88.0%)	0/ ()	27/30(90.0%)	0/ ()	50/50(100.0%)

¹Number of unassigned enrollment slots = 0.

²Number of participants actually enrolled (as numerator) and number of participants targeted to enroll (as denominator) in a given calendar month. Percentages of actual vs. target enrollment are given in parentheses.

³Number of participants actually enrolled and number of participants targeted to enroll up to a given calendar month.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Accrual Summary and Accrual by Calendar Month and Site
MALE**

	Total	San Francisco, CA	San Juan, PR	Seattle, WA	Washington DC
FEB2014	6/ () 398/400(99.5%)	0/ () 50/50(100.0%)	0/ () 22/25(88.0%)	0/ () 27/30(90.0%)	0/ () 50/50(100.0%)
MAR2014	5/ () 403/400(100.8%)	0/ () 50/50(100.0%)	0/ () 22/25(88.0%)	0/ () 27/30(90.0%)	0/ () 50/50(100.0%)
APR2014	3/ () 406/400(101.5%)	0/ () 50/50(100.0%)	0/ () 22/25(88.0%)	0/ () 27/30(90.0%)	0/ () 50/50(100.0%)
Average Enrolled per Month	18.4	2.6	1.2	1.4	2.7

¹Number of unassigned enrollment slots = 0.

²Number of participants actually enrolled (as numerator) and number of participants targeted to enroll (as denominator) in a given calendar month. Percentages of actual vs. target enrollment are given in parentheses.

³Number of participants actually enrolled and number of participants targeted to enroll up to a given calendar month.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Accrual Summary and Accrual by Calendar Month and Site
FEMALE**

	Total	Baltimore, MD	Boston, MA	Chapel Hill/ Raleigh, NC	Cleveland, OH					
Activation Date	28JUN2012	11SEP2012	15AUG2012	28JUN2012	11SEP2012					
First Enrollment Date	15MAR2013	18AUG2014	29MAY2013	15MAR2013	17APR2013					
Summary										
Total Enrolled	188	8	15	21	18					
Enrollment Target ¹	200	20	20	20	12					
Percent Enrolled	94.0%	40.0%	75.0%	105.0%	150.0%					
Accrual										
Calendar Month of Accrual	Month ²	Cumulative ³	Month	Cumulative	Month	Cumulative	Month	Cumulative	Month	Cumulative
FEB2013	0/1(0.0%)	0/1(0.0%)					0/1(0.0%)	0/1(0.0%)		
MAR2013	1/11(9.1%)	1/12(8.3%)			0/1(0.0%)	0/1(0.0%)	1/2(50.0%)	1/3(33.3%)	0/1(0.0%)	0/1(0.0%)
APR2013	6/28(21.4%)	7/40(17.5%)	0/3(0.0%)	0/3(0.0%)	0/3(0.0%)	0/4(0.0%)	1/3(33.3%)	2/6(33.3%)	1/2(50.0%)	1/3(33.3%)
MAY2013	5/30(16.7%)	12/70(17.1%)	0/3(0.0%)	0/6(0.0%)	1/3(33.3%)	1/7(14.3%)	0/2(0.0%)	2/8(25.0%)	0/2(0.0%)	1/5(20.0%)
JUN2013	8/30(26.7%)	20/100(20.0%)	0/3(0.0%)	0/9(0.0%)	2/3(66.7%)	3/10(30.0%)	0/2(0.0%)	2/10(20.0%)	0/2(0.0%)	1/7(14.3%)
JUL2013	6/30(20.0%)	26/130(20.0%)	0/3(0.0%)	0/12(0.0%)	3/3(100.0%)	6/13(46.2%)	1/2(50.0%)	3/12(25.0%)	0/2(0.0%)	1/9(11.1%)
AUG2013	13/30(43.3%)	39/160(24.4%)	0/3(0.0%)	0/15(0.0%)	3/3(100.0%)	9/16(56.3%)	0/2(0.0%)	3/14(21.4%)	0/2(0.0%)	1/11(9.1%)
SEP2013	10/24(41.7%)	49/184(26.6%)	0/3(0.0%)	0/18(0.0%)	1/3(33.3%)	10/19(52.6%)	0/2(0.0%)	3/16(18.8%)	0/1(0.0%)	1/12(8.3%)
OCT2013	7/13(53.8%)	56/197(28.4%)	0/2(0.0%)	0/20(0.0%)	1/1(100.0%)	11/20(55.0%)	0/2(0.0%)	3/18(16.7%)	1/ ()	2/12(16.7%)
NOV2013	10/3(333.3%)	66/200(33.0%)			0/ ()	11/20(55.0%)	0/2(0.0%)	3/20(15.0%)	3/ ()	5/12(41.7%)
DEC2013	11/ ()	77/200(38.5%)			0/ ()	11/20(55.0%)	0/ ()	3/20(15.0%)	3/ ()	8/12(66.7%)
JAN2014	8/ ()	85/200(42.5%)			0/ ()	11/20(55.0%)	0/ ()	3/20(15.0%)	1/ ()	9/12(75.0%)
FEB2014	7/ ()	92/200(46.0%)			0/ ()	11/20(55.0%)	0/ ()	3/20(15.0%)	3/ ()	12/12(100.0%)
MAR2014	8/ ()	100/200(50.0%)			0/ ()	11/20(55.0%)	0/ ()	3/20(15.0%)	1/ ()	13/12(108.3%)
APR2014	8/ ()	108/200(54.0%)			0/ ()	11/20(55.0%)	2/ ()	5/20(25.0%)	1/ ()	14/12(116.7%)
MAY2014	8/ ()	116/200(58.0%)			0/ ()	11/20(55.0%)	0/ ()	5/20(25.0%)	0/ ()	14/12(116.7%)
JUN2014	14/ ()	130/200(65.0%)			2/ ()	13/20(65.0%)	7/ ()	12/20(60.0%)	0/ ()	14/12(116.7%)
JUL2014	13/ ()	143/200(71.5%)			2/ ()	15/20(75.0%)	2/ ()	14/20(70.0%)	2/ ()	16/12(133.3%)
AUG2014	10/ ()	153/200(76.5%)	2/ ()	2/20(10.0%)	0/ ()	15/20(75.0%)	1/ ()	15/20(75.0%)	0/ ()	16/12(133.3%)
SEP2014	5/ ()	158/200(79.0%)	2/ ()	4/20(20.0%)	0/ ()	15/20(75.0%)	0/ ()	15/20(75.0%)	0/ ()	16/12(133.3%)
OCT2014	11/ ()	169/200(84.5%)	1/ ()	5/20(25.0%)	0/ ()	15/20(75.0%)	3/ ()	18/20(90.0%)	0/ ()	16/12(133.3%)

¹Number of unassigned enrollment slots = 0.

²Number of participants actually enrolled (as numerator) and number of participants targeted to enroll (as denominator) in a given calendar month. Percentages of actual vs. target enrollment are given in parentheses.

³Number of participants actually enrolled and number of participants targeted to enroll up to a given calendar month.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Accrual Summary and Accrual by Calendar Month and Site
FEMALE**

	Total		Baltimore, MD		Boston, MA		Chapel Hill/ Raleigh, NC		Cleveland, OH	
NOV2014	18/ ()	187/200(93.5%)	3/ ()	8/20(40.0%)	0/ ()	15/20(75.0%)	3/ ()	21/20(105.0%)	2/ ()	18/12(150.0%)
DEC2014	1/ ()	188/200(94.0%)	0/ ()	8/20(40.0%)	0/ ()	15/20(75.0%)	0/ ()	21/20(105.0%)	0/ ()	18/12(150.0%)
Average Enrolled per Month		8.1		0.6		0.6		0.9		0.8

¹Number of unassigned enrollment slots = 0.

²Number of participants actually enrolled (as numerator) and number of participants targeted to enroll (as denominator) in a given calendar month. Percentages of actual vs. target enrollment are given in parentheses.

³Number of participants actually enrolled and number of participants targeted to enroll up to a given calendar month.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Accrual Summary and Accrual by Calendar Month and Site
FEMALE**

	Total	Los Angeles, CA	New York, NY	Newark, NJ	Philadelphia, PA					
Activation Date	28JUN2012	13JUL2012	15AUG2012	20MAR2013	15AUG2012					
First Enrollment Date	15MAR2013	10DEC2013	25JUN2013	18APR2013	09MAY2013					
Summary										
Total Enrolled	188	5	16	32	15					
Enrollment Target ¹	200	20	12	20	12					
Percent Enrolled	94.0%	25.0%	133.3%	160.0%	125.0%					
Accrual										
Calendar Month of Accrual	Month ²	Cumulative ³	Month	Cumulative	Month	Cumulative	Month	Cumulative	Month	Cumulative
FEB2013	0/1(0.0%)	0/1(0.0%)								
MAR2013	1/11(9.1%)	1/12(8.3%)			0/2(0.0%)	0/2(0.0%)	0/2(0.0%)	0/2(0.0%)	0/1(0.0%)	0/1(0.0%)
APR2013	6/28(21.4%)	7/40(17.5%)	0/2(0.0%)	0/2(0.0%)	0/2(0.0%)	0/4(0.0%)	4/2(200.0%)	4/4(100.0%)	0/2(0.0%)	0/3(0.0%)
MAY2013	5/30(16.7%)	12/70(17.1%)	0/3(0.0%)	0/5(0.0%)	0/2(0.0%)	0/6(0.0%)	1/3(33.3%)	5/7(71.4%)	3/2(150.0%)	3/5(60.0%)
JUN2013	8/30(26.7%)	20/100(20.0%)	0/3(0.0%)	0/8(0.0%)	1/2(50.0%)	1/8(12.5%)	1/3(33.3%)	6/10(60.0%)	0/2(0.0%)	3/7(42.9%)
JUL2013	6/30(20.0%)	26/130(20.0%)	0/3(0.0%)	0/11(0.0%)	0/2(0.0%)	1/10(10.0%)	0/3(0.0%)	6/13(46.2%)	0/2(0.0%)	3/9(33.3%)
AUG2013	13/30(43.3%)	39/160(24.4%)	0/3(0.0%)	0/14(0.0%)	2/2(100.0%)	3/12(25.0%)	2/3(66.7%)	8/16(50.0%)	2/2(100.0%)	5/11(45.5%)
SEP2013	10/24(41.7%)	49/184(26.6%)	0/3(0.0%)	0/17(0.0%)	0/ ()	3/12(25.0%)	1/2(50.0%)	9/18(50.0%)	2/1(200.0%)	7/12(58.3%)
OCT2013	7/13(53.8%)	56/197(28.4%)	0/2(0.0%)	0/19(0.0%)	0/ ()	3/12(25.0%)	0/2(0.0%)	9/20(45.0%)	1/ ()	8/12(66.7%)
NOV2013	10/3(333.3%)	66/200(33.0%)	0/1(0.0%)	0/20(0.0%)	0/ ()	3/12(25.0%)	4/ ()	13/20(65.0%)	1/ ()	9/12(75.0%)
DEC2013	11/ ()	77/200(38.5%)	1/ ()	1/20(5.0%)	0/ ()	3/12(25.0%)	4/ ()	17/20(85.0%)	0/ ()	9/12(75.0%)
JAN2014	8/ ()	85/200(42.5%)	0/ ()	1/20(5.0%)	3/ ()	6/12(50.0%)	1/ ()	18/20(90.0%)	0/ ()	9/12(75.0%)
FEB2014	7/ ()	92/200(46.0%)	0/ ()	1/20(5.0%)	0/ ()	6/12(50.0%)	1/ ()	19/20(95.0%)	1/ ()	10/12(83.3%)
MAR2014	8/ ()	100/200(50.0%)	0/ ()	1/20(5.0%)	2/ ()	8/12(66.7%)	0/ ()	19/20(95.0%)	1/ ()	11/12(91.7%)
APR2014	8/ ()	108/200(54.0%)	0/ ()	1/20(5.0%)	1/ ()	9/12(75.0%)	0/ ()	19/20(95.0%)	0/ ()	11/12(91.7%)
MAY2014	8/ ()	116/200(58.0%)	1/ ()	2/20(10.0%)	2/ ()	11/12(91.7%)	1/ ()	20/20(100.0%)	0/ ()	11/12(91.7%)
JUN2014	14/ ()	130/200(65.0%)	0/ ()	2/20(10.0%)	0/ ()	11/12(91.7%)	2/ ()	22/20(110.0%)	0/ ()	11/12(91.7%)
JUL2014	13/ ()	143/200(71.5%)	0/ ()	2/20(10.0%)	0/ ()	11/12(91.7%)	3/ ()	25/20(125.0%)	2/ ()	13/12(108.3%)
AUG2014	10/ ()	153/200(76.5%)	0/ ()	2/20(10.0%)	0/ ()	11/12(91.7%)	6/ ()	31/20(155.0%)	0/ ()	13/12(108.3%)
SEP2014	5/ ()	158/200(79.0%)	1/ ()	3/20(15.0%)	0/ ()	11/12(91.7%)	0/ ()	31/20(155.0%)	1/ ()	14/12(116.7%)
OCT2014	11/ ()	169/200(84.5%)	1/ ()	4/20(20.0%)	1/ ()	12/12(100.0%)	1/ ()	32/20(160.0%)	0/ ()	14/12(116.7%)

¹Number of unassigned enrollment slots = 0.

²Number of participants actually enrolled (as numerator) and number of participants targeted to enroll (as denominator) in a given calendar month. Percentages of actual vs. target enrollment are given in parentheses.

³Number of participants actually enrolled and number of participants targeted to enroll up to a given calendar month.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Accrual Summary and Accrual by Calendar Month and Site
FEMALE**

	Total		Los Angeles, CA		New York, NY		Newark, NJ		Philadelphia, PA	
NOV2014	18/ ()	187/200(93.5%)	1/ ()	5/20(25.0%)	4/ ()	16/12(133.3%)	0/ ()	32/20(160.0%)	1/ ()	15/12(125.0%)
DEC2014	1/ ()	188/200(94.0%)	0/ ()	5/20(25.0%)	0/ ()	16/12(133.3%)	0/ ()	32/20(160.0%)	0/ ()	15/12(125.0%)
Average Enrolled per Month		8.1		0.2		0.7		1.4		0.6

¹Number of unassigned enrollment slots = 0.

²Number of participants actually enrolled (as numerator) and number of participants targeted to enroll (as denominator) in a given calendar month. Percentages of actual vs. target enrollment are given in parentheses.

³Number of participants actually enrolled and number of participants targeted to enroll up to a given calendar month.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Accrual Summary and Accrual by Calendar Month and Site
FEMALE**

	Total	Pittsburgh, PA	San Juan, PR	Seattle, WA	Washington DC					
Activation Date	28JUN2012	27SEP2012	19OCT2012	28AUG2012	28AUG2012					
First Enrollment Date	15MAR2013	14APR2014	03JUN2013	13JUN2013	26JUN2013					
Summary										
Total Enrolled	188	15	15	8	20					
Enrollment Target ¹	200	20	12	12	20					
Percent Enrolled	94.0%	75.0%	125.0%	66.7%	100.0%					
Accrual										
Calendar Month of Accrual	Month ²	Cumulative ³	Month	Cumulative	Month	Cumulative	Month	Cumulative	Month	Cumulative
FEB2013	0/1(0.0%)	0/1(0.0%)								
MAR2013	1/11(9.1%)	1/12(8.3%)					0/1(0.0%)	0/1(0.0%)	0/1(0.0%)	0/1(0.0%)
APR2013	6/28(21.4%)	7/40(17.5%)	0/3(0.0%)	0/3(0.0%)	0/1(0.0%)	0/1(0.0%)	0/2(0.0%)	0/3(0.0%)	0/3(0.0%)	0/4(0.0%)
MAY2013	5/30(16.7%)	12/70(17.1%)	0/3(0.0%)	0/6(0.0%)	0/2(0.0%)	0/3(0.0%)	0/2(0.0%)	0/5(0.0%)	0/3(0.0%)	0/7(0.0%)
JUN2013	8/30(26.7%)	20/100(20.0%)	0/3(0.0%)	0/9(0.0%)	2/2(100.0%)	2/5(40.0%)	1/2(50.0%)	1/7(14.3%)	1/3(33.3%)	1/10(10.0%)
JUL2013	6/30(20.0%)	26/130(20.0%)	0/3(0.0%)	0/12(0.0%)	1/2(50.0%)	3/7(42.9%)	0/2(0.0%)	1/9(11.1%)	1/3(33.3%)	2/13(15.4%)
AUG2013	13/30(43.3%)	39/160(24.4%)	0/3(0.0%)	0/15(0.0%)	1/2(50.0%)	4/9(44.4%)	1/2(50.0%)	2/11(18.2%)	2/3(66.7%)	4/16(25.0%)
SEP2013	10/24(41.7%)	49/184(26.6%)	0/3(0.0%)	0/18(0.0%)	0/2(0.0%)	4/11(36.4%)	0/1(0.0%)	2/12(16.7%)	6/3(200.0%)	10/19(52.6%)
OCT2013	7/13(53.8%)	56/197(28.4%)	0/2(0.0%)	0/20(0.0%)	1/1(100.0%)	5/12(41.7%)	0/ ()	2/12(16.7%)	3/1(300.0%)	13/20(65.0%)
NOV2013	10/3(333.3%)	66/200(33.0%)			1/ ()	6/12(50.0%)	0/ ()	2/12(16.7%)	1/ ()	14/20(70.0%)
DEC2013	11/ ()	77/200(38.5%)			2/ ()	8/12(66.7%)	0/ ()	2/12(16.7%)	1/ ()	15/20(75.0%)
JAN2014	8/ ()	85/200(42.5%)			1/ ()	9/12(75.0%)	1/ ()	3/12(25.0%)	1/ ()	16/20(80.0%)
FEB2014	7/ ()	92/200(46.0%)			0/ ()	9/12(75.0%)	1/ ()	4/12(33.3%)	1/ ()	17/20(85.0%)
MAR2014	8/ ()	100/200(50.0%)			2/ ()	11/12(91.7%)	1/ ()	5/12(41.7%)	1/ ()	18/20(90.0%)
APR2014	8/ ()	108/200(54.0%)	1/ ()	1/20(5.0%)	0/ ()	11/12(91.7%)	1/ ()	6/12(50.0%)	2/ ()	20/20(100.0%)
MAY2014	8/ ()	116/200(58.0%)	2/ ()	3/20(15.0%)	2/ ()	13/12(108.3%)	0/ ()	6/12(50.0%)	0/ ()	20/20(100.0%)
JUN2014	14/ ()	130/200(65.0%)	2/ ()	5/20(25.0%)	0/ ()	13/12(108.3%)	1/ ()	7/12(58.3%)	0/ ()	20/20(100.0%)
JUL2014	13/ ()	143/200(71.5%)	1/ ()	6/20(30.0%)	1/ ()	14/12(116.7%)	0/ ()	7/12(58.3%)	0/ ()	20/20(100.0%)
AUG2014	10/ ()	153/200(76.5%)	1/ ()	7/20(35.0%)	0/ ()	14/12(116.7%)	0/ ()	7/12(58.3%)	0/ ()	20/20(100.0%)
SEP2014	5/ ()	158/200(79.0%)	0/ ()	7/20(35.0%)	1/ ()	15/12(125.0%)	0/ ()	7/12(58.3%)	0/ ()	20/20(100.0%)
OCT2014	11/ ()	169/200(84.5%)	3/ ()	10/20(50.0%)	0/ ()	15/12(125.0%)	1/ ()	8/12(66.7%)	0/ ()	20/20(100.0%)

¹Number of unassigned enrollment slots = 0.

²Number of participants actually enrolled (as numerator) and number of participants targeted to enroll (as denominator) in a given calendar month. Percentages of actual vs. target enrollment are given in parentheses.

³Number of participants actually enrolled and number of participants targeted to enroll up to a given calendar month.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Accrual Summary and Accrual by Calendar Month and Site
FEMALE**

	Total		Pittsburgh, PA		San Juan, PR		Seattle, WA		Washington DC	
NOV2014	18/ ()	187/200(93.5%)	4/ ()	14/20(70.0%)	0/ ()	15/12(125.0%)	0/ ()	8/12(66.7%)	0/ ()	20/20(100.0%)
DEC2014	1/ ()	188/200(94.0%)	1/ ()	15/20(75.0%)	0/ ()	15/12(125.0%)	0/ ()	8/12(66.7%)	0/ ()	20/20(100.0%)
Average Enrolled per Month		8.1		0.9		0.7		0.3		0.9


¹Number of unassigned enrollment slots = 0.

²Number of participants actually enrolled (as numerator) and number of participants targeted to enroll (as denominator) in a given calendar month. Percentages of actual vs. target enrollment are given in parentheses.

³Number of participants actually enrolled and number of participants targeted to enroll up to a given calendar month.

**Maraviroc Phase II PrEP
Data as of January 31, 2016
Accrual Graph by Calendar Month - Total
MALES**

Total Enrolled: 406 Enrollment Target: 400 Enrollment Needed: 0




ected
ctual

Maraviroc Phase II PrEP Data as of January 31, 2016

Accrual Graph by Calendar Month - by Site MALES


Baltimore, MD

Total Enrolled: 23 Enrollment Target: 25 Enrollment Needed: 2




Boston, MA

Total Enrolled: 50 Enrollment Target: 50 Enrollment Needed: 0



Chapel Hill/Raleigh, NC

Total Enrolled: 35 Enrollment Target: 35 Enrollment Needed: 0




Maraviroc Phase II PrEP Data as of January 31, 2016

Accrual Graph by Calendar Month - by Site MALES


Los Angeles, CA

Total Enrolled: 30 Enrollment Target: 25 Enrollment Needed: 0




New York, NY

Total Enrolled: 29 Enrollment Target: 25 Enrollment Needed: 0




Philadelphia, PA

Total Enrolled: 32 Enrollment Target: 30 Enrollment Needed: 0



Pittsburgh, PA

Total Enrolled: 25 Enrollment Target: 25 Enrollment Needed: 0




**Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Accrual Graph by Calendar Month - by Site
MALES**


San Francisco, CA

Total Enrolled: 50 Enrollment Target: 50 Enrollment Needed: 0




San Juan, PR

Total Enrolled: 22 Enrollment Target: 25 Enrollment Needed: 3




Seattle, WA

Total Enrolled: 27 Enrollment Target: 30 Enrollment Needed: 3




Washington DC

Total Enrolled: 50 Enrollment Target: 50 Enrollment Needed: 0



**Maraviroc Phase II PrEP
Data as of January 31, 2016
Accrual Graph by Calendar Month - Total
FEMALES**

Total Enrolled: 188 Enrollment Target: 200 Enrollment Needed: 12




ected
ctual

Maraviroc Phase II PrEP Data as of January 31, 2016

Accrual Graph by Calendar Month - by Site FEMALES


Baltimore, MD

Total Enrolled: 8 Enrollment Target: 20 Enrollment Needed: 12




Boston, MA

Total Enrolled: 15 Enrollment Target: 20 Enrollment Needed: 5




Chapel Hill/Raleigh, NC

Total Enrolled: 21 Enrollment Target: 20 Enrollment Needed: 0



Cleveland, OH

Total Enrolled: 18 Enrollment Target: 12 Enrollment Needed: 0




**Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Accrual Graph by Calendar Month - by Site
FEMALES**


Los Angeles, CA

Total Enrolled: 5 Enrollment Target: 20 Enrollment Needed: 15




New York, NY

Total Enrolled: 16 Enrollment Target: 12 Enrollment Needed: 0




Newark, NJ

Total Enrolled: 32 Enrollment Target: 20 Enrollment Needed: 0



Philadelphia, PA

Total Enrolled: 15 Enrollment Target: 12 Enrollment Needed: 0




Maraviroc Phase II PrEP Data as of January 31, 2016

Accrual Graph by Calendar Month - by Site FEMALES


Pittsburgh, PA

Total Enrolled: 15 Enrollment Target: 20 Enrollment Needed: 5




San Juan, PR

Total Enrolled: 15 Enrollment Target: 12 Enrollment Needed: 0



Seattle, WA

Total Enrolled: 8 Enrollment Target: 12 Enrollment Needed: 4



Washington DC

Total Enrolled: 20 Enrollment Target: 20 Enrollment Needed: 0

